There has been significant debate over the identity of cancer stem cell populations in acute lymphoblastic leukaemia (ALL), with different groups reporting seemingly contradictory results. The latest findings suggest that tumour-propagating capacity is found within a high percentage of ALL blasts and that these cells have diverse immunophenotypes, which suggests that ALL follows a stochastic cancer stem cell model -as opposed to a hierarchical model. Recent data add a layer of complexity to the tumour evolution process by showing that the leukaemia-propagating compartment consists of multiple genetically diverse subclones related by Darwinian-style evolutionary trees.
In the early 1990s, pioneering work from John Dick's laboratory demonstrated that only a rare subset of malignant acute myeloid leukaemia (AML) cells could reconstitute the disease following successive xenotransplantations in mice. 1 This work was possible due to critical advances in haematopoietic stem cell (HSC) isolation based on surface marker expression profiles, 2 and provided the first experimental evidence for a concept that had been previously discussed for decades: the cancer stem cell (CSC). The CSC model contends that long-term tumour growth is driven by a population of cells with stem cell-like properties, resulting in the formation of tumours that are functionally and morphologically heterogeneous.
This heterogeneity can be explained by two CSC models. In the hierarchical model, CSCs are a biologically distinct subset of cells that both sustain the stem cell pool through self-renewal and give rise to progeny lacking extensive proliferative capacity. This model is analogous to the function of stem cells in normal tissue development.
It follows from this that elimination of the CSC compartment will result in cessation of tumour growth. In contrast, the stochastic model contends that all cells within a tumour have the potential to act as CSCs and that functional heterogeneity is influenced by other factors.
These could be either intrinsic (e.g., varying levels of particular transcription factors) or extrinsic (e.g., the tumour niche).
There is a substantial amount of evidence that the hierarchical model applies in some tumours. The initial findings of John Dick's laboratory, which have since been expanded upon, 3 showed that the long-term tumour-maintaining capacity in AML lies only within a rare subpopulation. Although other studies suggest the phenotype of these cells may be more diverse than initially thought, 4 Stem Cells in Acute Lymphoblastic Leukaemia
Clonal Evolution and Tumour Heterogeneity
The picture of the CSC compartment in leukaemia is complicated by the process of clonal evolution, which can lead to significant This suggests that mouse xenograft models are highly relevant for studying clonal selection processes in relapse patients.
Taken together, these studies demonstrate significant genetic diversity within leukaemia-propagating populations. This process of clonal evolution and selection adds an additional layer of complexity, which must be incorporated into CSC models. These data show that there is significant genetic variation among cells with self-renewing
properties, but when taken alone do not imply that such properties are common to every tumour cell. As such, the process of clonal evolution itself does not necessarily distinguish between the hierarchical and stochastic CSC models, as the Darwinian-style selection process would be expected to occur within a hierarchical CSC compartment. However, in combination with the data showing a high diversity and frequency of tumour-initiating cells, the high level of clonal diversity is consistent with the stochastic model for ALL and provides a mechanism by which a heterogeneous population of tumour-initiating cells can be generated. Clonal evolution also suggests that the propagating cell population evolves significantly through the tumour development process, meaning that their phenotypic properties may also vary at different stages of disease.
This could help explain some of the current controversies over the identity and frequency of CSC populations. The limited number of CNAs analysed in the work described in this section means that these methods will provide a significant underestimate of the true clonal complexity of the ALL samples. A strategy to uniquely and heritably mark individual leukaemia cells, for example using cellular barcoding, 40 would provide a more comprehensive picture of the stem cell frequency, clonal complexity and evolution of ALL.
Cell of Origin
Another factor that may affect tumour evolution is the cell from which the tumour originates -a distinct concept to that of the CSC.
The cell of origin refers to the normal cell that acquires the first oncogenic mutations, while the CSC refers to cells that propagate the tumour, so these cells may be phenotypically different.
Normal stem cells have often been suggested as the cell of origin, partly because they remain in tissues long enough to accumulate the mutations that drive oncogenic transformation. There is evidence that mutations in stem cells specifically drive cancer in some models.
For example, the targeted deletion of adenomatous polyposis coli (APC, a negative regulator of the Wnt pathway) in mouse intestinal crypt stem cells results in transformation and adenoma growth, while APC deletion in transit-amplifying cells does not. 41 There is also evidence that HSCs are involved in the pathogenesis of some leukaemias, including chronic myeloid and lymphoblastic leukaemias. 42, 43 However, the CSC hypothesis does not preclude the possibility that transformation occurs in more differentiated cell types, which then re-initiate stemness pathways. Lymphoid cells retain the ability to clonally expand even after maturation, so could be considered as unipotent stem cells. This means that reactivation of self-renewal programmes may be unnecessary in lymphoid tumours.
Indeed, it has been demonstrated that memory T and B cells share aspects of a self-renewal programme with long-term HSCs. 44 The Haematological Malignancies
human cord blood cells with MLL fusion genes and transplanting the cells into mice. 51 The authors studied immunoglobulin heavy chain (IgH) These results suggest that the TEL/AML1 translocation is able to generate a population of pre-leukaemic cells with stem cell-like features, which then acquire extra genetic changes to develop into leukaemia. This is also indicative of a hierarchy in the early stages of tumour development, although the standard NOD/SCID mice used may not efficiently engraft all potential leukaemia-initiating populations.
Together, both studies show that initiating ALL mutations can occur in primitive cells, which then undergo a clonal evolution process leading to the formation of a developed leukaemia-propagating population.
Further understanding of the cell of origin has come from the development of mouse models of cancer, in which oncogenic events can be targeted to specific cell types to assess whether they can 
Clinical Relevance and Conclusions
In summary, there remains a significant amount of debate over the applicability of CSC hypotheses to ALL. The most recent data, using mouse models with greater immunodeficiency, suggests that tumour-propagating capacity is present in B-ALL blasts at a much greater frequency than was initially thought, and that these mice and high risk of early relapse. 55 Together with the study showing that clonal evolution in xenograft mouse models is analogous to that in relapse, 39 these results show that using ALL xenograft models to investigate leukaemic stem cell frequencies are highly relevant to the study of patient disease.
An understanding of the biology of ALL-propagating cells, and their differences with both normal cells and any tumour cells that lack this capability, is a crucial step towards the development of therapies that specifically target CSCs. However, the apparent genetic diversity Stem Cells in Acute Lymphoblastic Leukaemia
survival of CML stem cells, 57 suggesting that addiction to the initiating oncogene may be different in stem cells compared with the bulk of the population. This finding again highlights the importance of understanding the underlying biology of the propagating population to allow complete eradication of the disease.
A recent study has identified HSC-and LSC-specific gene signatures in AML cell populations that display stem cell activity in xenograft assays. 58 The presence of these signatures was a significant determinant of patient survival, providing the first indication that
CSCs have relevance to clinical outcome. Another group has shown enrichment of this LSC signature, as well as a normal HSC signature, in early T-cell precursor ALL (ETP-ALL) samples. 59 ETP-ALL is an aggressive malignancy with poor outcome, so these results suggest that the enriched stem cell signature may be relevant in determining survival in some types of ALL. However, our results suggest there is a poor correlation between this gene signature and B-ALL blasts, and that the HSC signature is unable to distinguish between CD34 high and CD34 low blast populations. 27 This is not entirely surprising given the high frequency of leukaemia-initiating blasts compared with AML, and suggests that HSC gene signatures may have less clinical relevance in ALL.
As an alternative, the fact that mature lymphoid cells can clonally expand means they can be considered as unipotent stem cells. The high frequency of tumourigenic blasts in ALL suggests this concept can be applied to malignant as well as normal lymphoid development, meaning that ALL blasts may use a lymphoid self-renewal programme that is distinct from that of normal HSCs. The fact that we do not see clustering of ALL blasts and normal HSCs following analysis of the haematopoietic self-renewal signature supports this hypothesis.
It follows from this that future therapeutics could potentially exploit differences between lymphoid and HSC self-renewal programmes.
An improved understanding of the unique features that regulate clonal expansion in normal and malignant lymphoid cells is therefore a vital objective for the future. n
